MARKET

HRTX

HRTX

Heron Therapeutics Inc
NASDAQ
1.780
+0.040
+2.30%
After Hours: 1.779 -0.001 -0.06% 17:17 11/01 EDT
OPEN
1.750
PREV CLOSE
1.740
HIGH
1.805
LOW
1.745
VOLUME
911.14K
TURNOVER
--
52 WEEK HIGH
3.930
52 WEEK LOW
0.5000
MARKET CAP
269.97M
P/E (TTM)
-5.4786
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at HRTX last week (1021-1025)?
Weekly Report · 4d ago
Weekly Report: what happened at HRTX last week (1014-1018)?
Weekly Report · 10/21 10:58
Weekly Report: what happened at HRTX last week (1007-1011)?
Weekly Report · 10/14 11:23
Heron Therapeutics Reaffirms Treatment Supply After Hurricane Helene
Dow Jones · 10/10 21:06
*Heron Therapeutics: Potential Disruption in Supply of Intravenously Administered Fluids Is Result of Temporary Closure of Suppliers' Manufacturing Site in Marion, N.C., Impacted by Hurricane Helene >HRTX
Dow Jones · 10/10 20:30
*Heron Therapeutics: Marion Facility Is Believed to Supply Up to 60% of the IV Fluid Market in U.S. >HRTX
Dow Jones · 10/10 20:30
*Heron Therapeutics: CINVANTI, in Combination With Other Antiemetic Agents, Is Indicated in Adults for Prevention of Nausea and Vomiting Associated With Cancer Chemotherapy >HRTX
Dow Jones · 10/10 20:30
Heron Therapeutics reaffirms availability of Cinvant, Sustol and Aponvie
TipRanks · 10/10 20:15
More
About HRTX
Heron Therapeutics, Inc. is a commercial-stage biotechnology company. The Company commercializes a portfolio of products to care for acute care and oncology patients. Its oncology care product portfolio includes SUSTOL and CINVANTI. SUSTOL is used for the prevention of acute and delayed nausea and vomiting associated with both moderately emetogenic chemotherapy (MEC), and anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. CINVANTI is an intravenous (IV) formulation of aprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist. Its acute care product portfolio includes ZYNRELEF and APONVIE. HTX- ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is the IV formulation of a NK1 receptor antagonist indicated for postoperative nausea and vomiting (PONV). Its products are distributed in the United States.

Webull offers Heron Therapeutics Inc stock information, including NASDAQ: HRTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HRTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading HRTX stock methods without spending real money on the virtual paper trading platform.